Christine Lowe is a prominent inventor based in Northridge, CA (US). She has made significant contributions to the field of cancer treatment through her innovative work on antibody drug conjugates (ADCs). With a total of 2 patents, her research focuses on developing therapeutic compositions that target specific proteins associated with cancer.

Latest Patents

Christine's latest patents involve antibody drug conjugates that bind to FLT3 proteins. These ADCs are designed to target FLT3 protein and its variants, which exhibit a distinct expression pattern in normal adult tissues but are aberrantly expressed in various cancers. The therapeutic compositions derived from her inventions provide promising avenues for cancer treatment.

Career Highlights

Christine Lowe is currently associated with Agensys, Inc., where she continues to advance her research in the field of oncology. Her work has garnered attention for its potential to improve cancer therapies and patient outcomes.

Collaborations

Throughout her career, Christine has collaborated with notable colleagues, including Nandini Rudra-Ganguly and Gao Liu. These partnerships have contributed to the development and refinement of her innovative approaches in cancer treatment.

Conclusion

Christine Lowe's contributions to the field of antibody drug conjugates represent a significant advancement in cancer therapy. Her dedication to innovation and collaboration continues to inspire progress in medical research.

Profile summary based on public USPTO records.